Published in World J Transplant on September 24, 2016
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 9.82
Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med (2001) 8.69
The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 7.82
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11
Gene map of the extended human MHC. Nat Rev Genet (2004) 6.01
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Cancer after kidney transplantation in the United States. Am J Transplant (2004) 5.08
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 4.69
CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med (2007) 4.66
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood (2011) 4.57
Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol (2004) 3.62
CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol (1991) 3.47
Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med (1999) 3.41
CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol (2002) 3.41
A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A (1994) 3.33
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A (1997) 3.25
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Immune functions encoded by the natural killer gene complex. Nat Rev Immunol (2003) 3.21
Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 3.17
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet (2009) 2.73
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res (2014) 2.66
Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer (2004) 2.65
High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens (2009) 2.64
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Global diversity and evidence for coevolution of KIR and HLA. Nat Genet (2007) 2.40
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med (2004) 2.39
The beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature (1975) 2.29
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant (2003) 2.22
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med (2001) 2.22
High-throughput, high-fidelity HLA genotyping with deep sequencing. Proc Natl Acad Sci U S A (2012) 2.03
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2010) 1.99
Identification of multiple HTF-island associated genes in the human major histocompatibility complex class III region. EMBO J (1989) 1.97
Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol (2002) 1.85
Graft-versus-leukemia reactions in allogeneic chimeras. Blood (2003) 1.84
A multi-site study using high-resolution HLA genotyping by next generation sequencing. Tissue Antigens (2011) 1.81
Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res (2014) 1.79
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2005) 1.60
IPD--the Immuno Polymorphism Database. Nucleic Acids Res (2009) 1.58
Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. Philos Trans R Soc Lond B Biol Sci (2012) 1.55
The molecular genetics of blood group polymorphism. Hum Genet (2009) 1.50
The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol (2006) 1.46
Leukocyte Ig-like receptor complex (LRC) in mice and men. Trends Immunol (2002) 1.45
Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal. Clin Transplant (2015) 1.41
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant (2009) 1.41
Next-generation sequencing: methodology and application. J Invest Dermatol (2013) 1.34
T cell receptor-MHC interactions up close. Cell (2001) 1.31
MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol (2001) 1.31
Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J Immunol (2002) 1.27
Multi-locus HLA class I and II allele and haplotype associations with follicular lymphoma. Tissue Antigens (2012) 1.22
Regulatory T cells and organ transplantation. Semin Immunol (2004) 1.22
Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation (2008) 1.22
Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation (2004) 1.21
Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant (2008) 1.20
The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant (2007) 1.19
Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood (2008) 1.19
Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1----2Gal alpha 1----3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem (1990) 1.15
Antibody-mediated rejection in kidney transplantation: a review. J Transplant (2012) 1.12
Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol (1999) 1.08
Blood group genotyping: from patient to high-throughput donor screening. Vox Sang (2009) 1.05
Extensive polymorphism of ABO blood group gene: three major lineages of the alleles for the common ABO phenotypes. Hum Genet (1996) 1.03
The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol (2012) 1.03
CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism. Transplantation (1996) 1.02
Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant (2009) 1.02
Organ transplantation: historical perspective and current practice. Br J Anaesth (2012) 1.01
Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) (2009) 1.00
Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood (2011) 0.99
HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation (2011) 0.99
Human leucocyte antigen typing: techniques and technology, a critical appraisal. Int J Immunogenet (2011) 0.97
Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol (2014) 0.96
Natural killer cells and their receptors. Transpl Immunol (2002) 0.95
MICA sequences 2000. Immunogenetics (2001) 0.95
Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant (2007) 0.95
Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs (2009) 0.94
Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol (2008) 0.92
Immune tolerance and transplantation. Semin Oncol (2012) 0.90
Current Bioengineering Methods for Whole Kidney Regeneration. Stem Cells Int (2015) 0.89
Role of MICA in the immune response to transplants. Tissue Antigens (2010) 0.86
Complement-mediated microvascular injury leads to chronic rejection. Adv Exp Med Biol (2013) 0.85
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2015) 0.85
The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques. J Clin Pathol (2010) 0.84
Immunotherapeutic applications of NK cells. Pharmaceuticals (Basel) (2015) 0.84
MICA variant promotes allosensitization after kidney transplantation. J Am Soc Nephrol (2013) 0.83
Kidney diseases and tissue engineering. Methods (2015) 0.83
Hematopoietic stem cell expansion and generation: the ways to make a breakthrough. Blood Res (2015) 0.82
Transplant tolerance: new insights and strategies for long-term allograft acceptance. Clin Dev Immunol (2013) 0.80
Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant (1997) 0.79
KIR-HLA mismatching in human renal allograft transplantation: emergence of a new concept. Am J Transplant (2011) 0.78
Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products. Transfusion (2012) 0.78
Further polymorphism of the MICA gene. Eur J Immunogenet (2002) 0.78
Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl Int (2001) 0.78
The role of the killer cell immunoglobulin-like receptor (KIR) "missing self" model in unrelated donor HSCT: a meta-analysis. Transplant Proc (2015) 0.77
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Paediatr Drugs (2003) 0.77